STOCK TITAN

Millennium Group (CABA) jointly reports 5.3% holding of 5.13M shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Cabaletta Bio, Inc. Schedule 13G reports that Millennium Management LLC, together with Millennium Group Management LLC and Israel A. Englander, beneficially hold 5,130,763 shares of common stock, representing 5.3% of the class.

The filing states the holders report shared voting power and shared dispositive power over the 5,130,763 shares and includes a Joint Filing Agreement dated February 17, 2026.

Positive

  • None.

Negative

  • None.

Insights

Joint filing shows coordinated disclosure of a 5.3% stake.

The filing lists shared voting power and shared dispositive power over 5,130,763 shares as reported on the cover pages. The owners executed a Joint Filing Agreement dated February 17, 2026.

Implications depend on future amendments or schedules disclosing changes; subsequent filings would show any change in voting or disposition rights.

A 5.3% position is a notable passive holding but not a controlling stake.

The disclosed 5,130,763 shares equals 5.3% of the class according to Item 11 on the cover pages. The reporting persons disclaim construing that figure as an admission of beneficial ownership beyond the disclosed voting/dispositive powers.

Market impact will depend on whether these holders buy, sell, or file different schedules in the future; timing and cash‑flow treatment are not stated here.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Millennium Management LLC
Signature:/s/ Gil Raviv
Name/Title:Gil Raviv, Global General Counsel
Date:02/17/2026
Millennium Group Management LLC
Signature:/s/ Gil Raviv
Name/Title:Gil Raviv, Global General Counsel
Date:02/17/2026
Israel A. Englander
Signature:/s/ Israel A. Englander
Name/Title:Israel A. Englander
Date:02/17/2026
Exhibit Information

Exhibit I: Joint Filing Agreement, dated as of February 17, 2026, by and among Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.

FAQ

What stake does Millennium report in Cabaletta Bio (CABA)?

The filing reports 5,130,763 shares, representing 5.3% of Cabaletta Bio's common stock. The shares are reported with shared voting and shared dispositive power by the listed filers under a joint filing agreement dated February 17, 2026.

Who filed the Schedule 13G for CABA?

The Schedule 13G was filed jointly by Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander. The filing includes addresses at 399 Park Avenue, New York, and signatures dated February 17, 2026.

Does the 13G indicate sole voting control of CABA shares?

No. The cover pages report 0 shares of sole voting power and 5,130,763 shares of shared voting power. The filing therefore discloses shared, not sole, voting authority over the reported shares.

Is the reported ownership in CABA admitted as beneficial ownership?

The filing states that the reported securities are held by entities subject to voting and investment discretion by the filers and cautions that this should not be construed as an admission of beneficial ownership by the filers.

What agreement among the filers is included in the CABA filing?

The filing includes an Exhibit I: Joint Filing Agreement dated February 17, 2026 among Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander, reflecting the joint reporting arrangement.
Cabaletta Bio, Inc.

NASDAQ:CABA

CABA Rankings

CABA Latest News

CABA Latest SEC Filings

CABA Stock Data

302.27M
94.64M
Biotechnology
Biological Products, (no Diagnostic Substances)
Link
United States
PHILADELPHIA